An mRNA Tumor Nanovaccine Expressing Tumor Antigen Fused With Angiotensin II Facilitates Type 1 Conventional Dendritic Cell‐Mediated Anti‐Tumor Immunity
Small · 2026-06 · 22 (32)
DOI: 10.1002/smll.202513524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 27.04.2026. Verfasst von Chunyuan Xie und 21 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Angiotensin II, Antigens, Neoplasm, Cancer Vaccines, Dendritic Cells. Die Arbeit nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Department of Science and Technology of Guangdong Province (Guangdong-Hong Kong Technology Cooperation Funding Scheme), Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
mRNA‐based tumor vaccines have shown great potential as a promising immunotherapeutic approach with encouraging preclinical and clinical results. However, how to enhance the antigen presentation efficiency of mRNA‐encoded tumor antigens and the intensity of vaccine‐induced CD8 + T cell response remains a great challenge. In this study, an antigen‐angiotensin II (ANG II) fusion mRNA nanovaccine that can enhance the immunogenicity of tumor antigens to promote CD8 + T cell immunity for effective tumor inhibition is developed. Furthermore, this mRNA nanovaccine is delivered by lipid nanoparticles (LNPs) composed of cationic lipid‐like material C1 and L‐phenylalanine‐based poly (ester amide) 8p4, which promotes the maturation of dendritic cells (DCs) and increases the type 1 conventional DC (cDC1) subpopulation, together enhancing the antigen presentation function of DCs for eliciting potent antigen‐specific CD8 + T cell response. Vaccination with the antigen‐ANG II mRNA nanovaccine expressing different tumor antigens effectively inhibited tumor growth on multiple mouse tumor models, which was greatly compromised in the cDC1‐deficient Batf3 −/− mice. Overall, this work provides an antigen‐ANG II fusion mRNA tumor nanovaccine platform with remarkable antitumor efficacy via triggering cDC1‐mediated CD8 + T cell response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Jiangxi Provincial Key Laboratory for Precision Pathology and Intelligent Diagnosis, Department of Pathology and Institute of Molecular Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang Univers…
- Bioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou, China.
- Center For Nanomedicine and Department of Anesthesiology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Pathology, School of Basic Medical Sciences, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Guangdong Province Key Laboratory of Molecular Tumor Pathology, Guangzhou, China.
ORCID-Profile: Xiaojun Xia
Förderung
- National Natural Science Foundation of China
- Department of Science and Technology of Guangdong Province (Guangdong-Hong Kong Technology Cooperation Funding Scheme)
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Xie, C., Guo, H., Dai, C., Wang, L., Yao, R., Cui, L., You, X., Wang, Z., Zhang, H., Zhang, H., Li, L., Wang, T., Guo, Z., Lin, Y., Yi, J., Wu, J., Xue, J., Jin, H., Zhao, Y., …, & Xia, X. (2026). An mRNA Tumor Nanovaccine Expressing Tumor Antigen Fused With Angiotensin II Facilitates Type 1 Conventional Dendritic Cell‐Mediated Anti‐Tumor Immunity. Small, 22(32). https://doi.org/10.1002/smll.202513524
Vancouver
Xie C, Guo H, Dai C, Wang L, Yao R, Cui L, et al. An mRNA Tumor Nanovaccine Expressing Tumor Antigen Fused With Angiotensin II Facilitates Type 1 Conventional Dendritic Cell‐Mediated Anti‐Tumor Immunity. Small. 2026;22(32). doi:10.1002/smll.202513524
BibTeX
@article{Xie2026,
author = {Xie, Chunyuan and Guo, Hui and Dai, Chunlei and Wang, Liying and Yao, Ruhui and Cui, Lei and You, Xinru and Wang, Zining and Zhang, Hongxia and Zhang, Huanling and Li, Lin and Wang, Tiantian and Guo, Zixuan and Lin, Yanxun and Yi, Jiahong and Wu, Jiaxin and Xue, Ju and Jin, Huan and Zhao, Yue and Wu, Zhiming and Wu, Jun and Xia, Xiaojun},
title = {An mRNA Tumor Nanovaccine Expressing Tumor Antigen Fused With Angiotensin II Facilitates Type 1 Conventional Dendritic Cell‐Mediated Anti‐Tumor Immunity},
journal = {Small},
year = {2026},
volume = {22},
number = {32},
doi = {10.1002/smll.202513524}
}
EUVIMED